Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
Portfolio Pulse from
Sunshine Biopharma has signed a strategic agreement to acquire marketing rights for two new generic antibiotics in Canada, expanding its portfolio through its subsidiary Nora Pharma. The global antibiotics market is projected to grow from $53.9 billion in 2024 to $85.8 billion by 2033, with a 5.3% CAGR. The Canadian market represents approximately 2.2% of the global market.
March 24, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Company expands generic drug portfolio with two new antibiotics, potentially increasing revenue and market share in the Canadian pharmaceutical market.
The acquisition of marketing rights for two new antibiotics directly enhances Sunshine Biopharma's product portfolio in Canada, potentially driving revenue growth and market expansion.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100